Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells

Figure 4

Dose response for mithramycin (plicamycin) in malignant cell lines. (a) PC3-TR, (b) PC3 human prostate cancer cells, and (c) Panc-1 pancreatic cancer cells. Single-agent treatments are shown as "dark grey diamonds" and combination treatments with 10 ng/mL of TRAIL are shown as "light grey squares". Asterisks (*) and (**) indicate p-values < 0.05 and < 0.01, respectively. (d) molecular structure of mithramycin. Arrows indicate the concentrations at which the enhancement in viability reduction is the greatest. Data are presented on a logarithmic scale and the lines connecting data points are for visualization only.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us